Muvon Therapeutics Announces Successful Phase I Clinical Study using a Novel Regenerative Cell Therapy
09-09-2022 – MUVON Therapeutics AG presented today at the International Continence Society (ICS) Annual Meeting in Vienna, the study findings showing the successful completion of Phase I with clinical data using its proprietary cell-therapy platform
This is another milestone in their path to reach the goal of helping millions of patients suffering from serious debilitating diseases and regain control of their lives by offering them minimally invasive treatment for regeneration of skeletal muscle.
